# US 11,896,733 B2 · Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,733 B2
- Document ID: US11896733B2
- Status: Granted
- Kind: B2
- Application number: 17/374,662
- Filed: 2021-07-13
- Published: 2021-11-04
- Granted: 2024-02-13
- Earliest claimed: 2010-04-09
- Assignees: 3M Innovative Properties Company
- Applicants: KCI Licensing, Inc.
- Inventors: Dmitry Zimnitsky; Jenny Finkbiner; Blane Sanders
- Web page: https://patentgrep.com/patent/US11896733B2

## CPC

- A61L 26/0038: {Gelatin}
- A61F 13/05: specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/381: having five-membered rings
- A61K 31/785: Polymers containing nitrogen
- A61K 33/26: Iron; Compounds thereof
- A61L 26/0066: {Medicaments; Biocides}
- A61M 1/915: {Constructional details of the pressure distribution manifold}
- A61F 2013/0017: {possibility of applying fluid}
- A61F 2013/00174: {possibility of applying pressure}
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2300/414: Growth factors
- A61L 2300/434: of enzymes
- A61M 1/85: {with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants (for negative pressure wound therapy A61M1/92, A61M1/94; combined with tracheal tubes A61M16/0463; dental instruments with combined rinsing and aspirating A61C17/0208)}
- A61M 1/92: {with liquid supply means}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.

## Claims

### Claim 1

A dressing for treating a tissue site, comprising:
a manifold comprising an open-cell foam having a plurality of flow channels adapted to distribute reduced pressure through the manifold; and
a composition for reducing excessive matrix metalloprotease activity coated on at least a portion of the manifold, wherein the composition comprises:
a gelatin substrate as a sacrificial proteolytic enzyme substrate,
a lipoic acid derivative, and
a chelating agent capable of reducing matrix metalloprotease activity.

### Claim 2 (depends on 1)

The dressing of claim 1, wherein the gelatin substrate comprises exposed peptide sequences adapted to serve as signals for matrix metalloprotease binding.

### Claim 3 (depends on 1)

The dressing of claim 1, wherein the lipoic acid derivative comprises a pharmaceutically-acceptable salt.

### Claim 4 (depends on 1)

The dressing of claim 1, wherein the lipoic acid derivative is alpha-lipoic acid or a pharmaceutically-acceptable salt of alpha-lipoic acid.

### Claim 5 (depends on 1)

The dressing of claim 1, wherein the composition comprises 0.1% to 25% w/w gelatin substrate.

### Claim 6 (depends on 1)

The dressing of claim 1, wherein the composition comprises 0.1% to 5% w/v lipoic acid derivative.

### Claim 7 (depends on 1)

The dressing of claim 1, wherein the composition further comprises an antimicrobial agent, a growth factor, or a preservative.

### Claim 8 (depends on 7)

The dressing of claim 7, wherein the antimicrobial agent is non-ionic silver, polyhexamethylene biguanide, chlorhexidine, benzalkonium chloride, or triclosan.

### Claim 9 (depends on 1)

The dressing of claim 1, wherein the chelating agent comprises ethylenediaminetetraacetic acid.

### Claim 10 (depends on 1)

The dressing of claim 1, wherein the manifold comprises an open-cell polyurethane foam.

### Claim 11 (depends on 1)

The dressing of claim 1, further comprising a scaffold adapted to be positioned between the manifold and the tissue site, wherein the scaffold has a plurality of passages.

### Claim 12 (depends on 11)

The dressing of claim 11, further comprising a release layer adapted to be positioned between the scaffold and the manifold.

### Claim 13

A composition for applying to a tissue dressing for reducing excessive matrix metalloprotease activity, comprising:
a sacrificial matrix metalloprotease substrate comprising gelatin and having exposed peptide sequences adapted to serve as signals for matrix metalloprotease binding;
a lipoic acid derivative; and
a chelating agent comprising ethylenediaminetetraacetic acid for reducing matrix metalloprotease activity.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the lipoic acid derivative comprises a pharmaceutically-acceptable salt.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the lipoic acid derivative is alpha-lipoic acid or a pharmaceutically-acceptable salt of alpha-lipoic acid.

### Claim 16 (depends on 13)

The composition of claim 13, wherein the composition comprises 0.1% to 25% w/w gelatin substrate.

### Claim 17 (depends on 13)

The composition of claim 13, wherein the composition comprises 0.1% to 5% w/v lipoic acid derivative.

### Claim 18 (depends on 13)

The composition of claim 13, further comprising an antimicrobial agent, a growth factor, or a preservative.

### Claim 19

A wound dressing, comprising:
a porous polyurethane material; and
a composition comprising a sacrificial proteolytic enzyme substrate and a lipoic acid derivative, the composition provided on at least a portion of the porous polyurethane material;
wherein the lipoic acid derivative is a dihydrolipoic acid comprising the structure:
wherein n1 and n2 are, independently, C1-C10 alkyl;
R1 is H, C1-C10 alkyl, C6-C14 aryl, an alkyl ammonium or a protonated amino acid; and
R2 is H, C1-C10 alkyl or C6-C14 aryl.

### Claim 20 (depends on 19)

The wound dressing of claim 19, wherein the composition further comprises an antimicrobial agent, a growth factor, a proteinase inhibitor, a chelating agent or a preservative.